8 results about "Intracellular bacterium" patented technology

The application provides a double-strand DNA vaccine for late Edwardsiella tarda disease, which can significantly induce Th1 type immune bias, enhance fish cell immune response, improve the resistance to intracellular bacterial infection, and has the advantages of safety and high efficiency, easy preparation, strong adaptability for on-site promotion and the like. The double-strand DNA vaccine uses a fusion fragment of an immune adjuvant IL-12, which is constructed by connecting a nucleic acid fragment coding a subunit 12p35 with an amino acid sequence of SEQ ID NO:1 and a nucleic acid fragment coding a subunit 12p40 with an amino acid sequence of SEQ ID NO:3 through a flexible connecting peptide linker. The double-strand DNA vaccine realizes the synergistic expression of OmpC antigen and IL-12 adjuvant, enhances immunogenicity, and solves the problem of insufficient immune effect of a traditional DNA vaccine; and the vaccine has no obvious toxic side effect on fish bodies, is not dependent on the use of antibiotics, is green and environmentally friendly, and has a good industrialization prospect.

The application belongs to the technical field of microorganism detection, and discloses a method for extracting intracellular bacteria of ameba in a water environment and environmental application; the method comprises the following steps: S1, filtering a water environment sample and ameba enrichment culture; S2, removing extracellular bacteria attached to ameba by coupling treatment of a chelating agent and lysozyme; S3, releasing intracellular bacteria by lysing ameba by using a lysing agent in combination with mechanical suction; and S4, centrifugation and filtration purification to obtain pure intracellular bacteria; the application is simple in operation, low in cost, high in bacterial purity, and can be used for water environment microorganism detection, drinking water safety monitoring, and provides technical support for ameba and intracellular bacteria interaction research.

The invention discloses a mechanical phenotype analysis chip for screening bacterial infected circulating tumor cells, and belongs to application of a micro-fluidic chip technology in the field of biomedical in-vitro diagnosis. The system comprises a micro-fluidic chip and a detection solution. The micro-fluidic chip comprises a sample introduction end, a shunting flow channel, a main flow channel and a sample discharge end, wherein single-cell mechanical property analysis function unit arrays are uniformly distributed on the two sides of the main flow channel in a staggered manner; and the single cell mechanical property analysis functional unit comprises a hook-shaped structure for single cell anchoring and a deformation channel structure for single cell mechanical property analysis. The detection solution comprises a fluorescent probe capable of specifically recognizing bacteria in cells. According to the micro-fluidic chip disclosed by the invention, single cell capture, mechanical property analysis and intracellular bacteria detection can be integrated on the same chip, and a time-saving, low-cost and high-throughput single cell detection platform can be constructed, so that visual detection of single cell mechanical phenotypes and intracellular bacteria is realized; the method can be used for evaluating the metastasis potential of the circulating tumor cells in the bacterial infection breast cancer.

This invention discloses broad-spectrum antibacterial peptides WP-4 and WP-6, their compositions, and applications, belonging to the fields of antimicrobial peptide technology and biomedicine. This invention obtains a series of antimicrobial peptides by truncating and rationally modifying template peptides to balance the relationship between charge number, hydrophobicity, and amphiphilicity. By measuring antibacterial activity, stability, hemolytic activity, and cytotoxicity, two novel antimicrobial peptides, WP-4 and WP-6, with high activity and low toxicity were obtained, and their amino acid sequences are shown in SEQ ID NO. 5 and SEQ ID NO. 7. The novel antimicrobial peptides obtained by this invention possess broad-spectrum antibacterial activity, good stability under temperature, pH, salt ion, pepsin, and serum conditions, and exhibit no significant hemolytic activity and low cytotoxicity. They are characterized by rapid bactericidal action and low likelihood of inducing drug resistance. Furthermore, the antimicrobial peptides of this invention can enter cells and have a strong inhibitory effect on intracellular bacteria, showing broad application prospects.

The invention discloses a detection method of eukaryotic single cells and bacteria carried by the eukaryotic single cells and application of the detection method. The detection method comprises the following steps: providing pretreated eukaryotic single cells and bacteria carried by the eukaryotic single cells; providing a multiple reverse transcription primer system, and carrying out reverse transcription reaction on the multiple reverse transcription primer system, the pretreated eukaryotic single cell and the bacteria carried by the eukaryotic single cell to obtain a reverse transcription product; providing a microbead which is provided with a cell label, mixing the microbead with the reverse transcription product, and carrying out a ligation reaction so as to label the cell label on the reverse transcription product, thereby obtaining a ligation product; performing library construction on the connection product to obtain a single cell transcriptome library and a 16S rRNA library, and sequencing to obtain interaction information between eukaryotic single cells and bacteria carried by the eukaryotic single cells; host cell RNA and intracellular bacteria rRNA are subjected to efficient reverse transcription through a multiple reverse transcription primer system, and a host single cell transcriptome library and a 16S variable region library are constructed respectively, so that simultaneous detection of host cells and intracellular bacteria is realized.

The invention relates to the technical field of biological medicines, in particular to a nano-drug for removing intracellular bacteria as well as a preparation method and application of the nano-drug. The nano-drug is composed of hollow mesoporous nano-particles, an antibacterial drug loaded in the hollow mesoporous nano-particles, metabolism activation molecules grafted on the surfaces of the particles, and an immune cell fusion membrane coated on the outermost layer and pre-stimulated by inactivated bacteria. Through a synergistic effect mechanism of metabolism activation, targeted sterilization and immune awakening, the technical problems of intracellular bacterial metabolism dormancy, low drug targeted delivery efficiency and host immunosuppression microenvironment which are difficult to overcome in the prior art are effectively solved. Experiments show that the nano-drug can specifically target an infected part, reverse a bacterial metabolism dormancy state and synchronously realize efficient sterilization and immune activation, shows an excellent clearing effect in treatment of intracellular infection caused by staphylococcus aureus and the like, and can effectively establish lasting immune memory and remarkably reduce the infection recurrence rate.

The subject matter described herein is directed to tolfenpyrad derivatives of Formula I, or pharmaceutically acceptable salts thereof, which exhibit antibacterial activity against Francisella species with little to no toxicity to mammalian cells. Pharmaceutical compositions of tolfenpyrad derivatives, and methods of treating disorders associated with Gram-negative intracellular bacterial pathogens, such as Francisella tularensis, are also described.

CFU-less assays of quantifying intracellular bacteria and methods of using the CFU-less assays to identify host-targeting modulators of pathogen uptake or killing by host cells are described. Also described are host-targeting modulators of pathogen uptake by host cells and methods of using the host-targeting modulators to treat infection